| Attribute |
Value |
| 52 Week Change |
-0.5153153 |
| Address1 |
3,710 - 33rd Street NW |
| All Time High |
2,478.6 |
| All Time Low |
1.725 |
| Ask |
2.67 |
| Ask Size |
3 |
| Average Daily Volume10 Day |
7,497,290 |
| Average Daily Volume3 Month |
1,258,313 |
| Average Volume |
1,258,313 |
| Average Volume10Days |
7,497,290 |
| Beta |
0.086 |
| Bid |
2.67 |
| Bid Size |
3 |
| Book Value |
1.497 |
| City |
Calgary |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Canada |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
2.69 |
| Current Ratio |
2.105 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,774,915,200 |
| Day High |
3.6 |
| Day Low |
2.53 |
| Debt To Equity |
1.789 |
| Display Name |
XORTX Therapeutics |
| Earnings Timestamp End |
1,778,788,800 |
| Earnings Timestamp Start |
1,778,788,800 |
| Ebitda |
-2,508,489 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-1.163 |
| Enterprise Value |
2,918,447 |
| Eps Forward |
0.8018253 |
| Eps Trailing Twelve Months |
-2.8 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
2.1366 |
| Fifty Day Average Change |
0.55340004 |
| Fifty Day Average Change Percent |
0.25900966 |
| Fifty Two Week Change Percent |
-51.53153 |
| Fifty Two Week High |
7.05 |
| Fifty Two Week High Change |
-4.36 |
| Fifty Two Week High Change Percent |
-0.61843973 |
| Fifty Two Week Low |
1.725 |
| Fifty Two Week Low Change |
0.96500003 |
| Fifty Two Week Low Change Percent |
0.5594203 |
| Fifty Two Week Range |
1.725 - 7.05 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,632,403,800,000 |
| Float Shares |
1,367,951 |
| Forward Eps |
0.8018253 |
| Forward P E |
3.3548455 |
| Free Cashflow |
-1,856,310 |
| Full Exchange Name |
NasdaqCM |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.10261 |
| Held Percent Institutions |
0.058709998 |
| Implied Shares Outstanding |
1,553,127 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,021-10-13 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,775,433,600 |
| Last Split Factor |
1:5 |
| Long Business Summary |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada. |
| Long Name |
XORTX Therapeutics Inc. |
| Market |
us_market |
| Market Cap |
4,177,911 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_259860883 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
-2,656,304 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
4,421,468 |
| Open |
2.94 |
| Operating Cashflow |
-2,768,723 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Phone |
403-455-7727 |
| Pre Market Change |
-0.2650001 |
| Pre Market Change Percent |
-9.851305 |
| Pre Market Price |
2.425 |
| Pre Market Time |
1,776,849,026 |
| Previous Close |
2.25 |
| Price Hint |
4 |
| Price To Book |
1.7969272 |
| Profit Margins |
0.0 |
| Quick Ratio |
1.577 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.44 |
| Regular Market Change Percent |
19.5556 |
| Regular Market Day High |
3.6 |
| Regular Market Day Low |
2.53 |
| Regular Market Day Range |
2.53 - 3.6 |
| Regular Market Open |
2.94 |
| Regular Market Previous Close |
2.25 |
| Regular Market Price |
2.69 |
| Regular Market Time |
1,776,801,600 |
| Regular Market Volume |
73,026,910 |
| Return On Assets |
-0.46839002 |
| Return On Equity |
-0.98001 |
| Sand P52 Week Change |
0.3140242 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
1,546,988 |
| Shares Percent Shares Out |
0.0028 |
| Shares Short |
3,887 |
| Shares Short Previous Month Date |
1,772,150,400 |
| Shares Short Prior Month |
28,855 |
| Short Name |
XORTX Therapeutics Inc. |
| Short Percent Of Float |
0.0029 |
| Short Ratio |
0.39 |
| Source Interval |
15 |
| State |
AB |
| Symbol |
XRTX |
| Total Cash |
864,514 |
| Total Cash Per Share |
0.621 |
| Total Debt |
37,287 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-2.8 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
3.205525 |
| Two Hundred Day Average Change |
-0.51552486 |
| Two Hundred Day Average Change Percent |
-0.16082385 |
| Type Disp |
Equity |
| Volume |
73,026,910 |
| Website |
https://www.xortx.com |
| Zip |
T2L 2M1 |